Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

被引：8

作者：

Yu, E. ^{[1
]}

Piulats, J. M. ^{[2
]}

Gravis, G. ^{[3
]}

Fong, P. C. C. ^{[4
]}

Todenhoefer, T. ^{[5
]}

Laguerre, B. ^{[6
]}

Arranz Arija, J. A. ^{[7
]}

Oudard, S. ^{[8
]}

Massard, C. ^{[9
,10
]}

Stoeckle, M. ^{[11
]}

Nordquist, L. T. ^{[12
]}

Carles, J. ^{[13
]}

Kolinsky, M. P. ^{[14
]}

Augustin, M. ^{[15
]}

Gurney, H. ^{[16
,17
]}

Tafreshi, A. ^{[18
]}

Li, X. T. ^{[19
]}

Poehlein, C. H. ^{[19
]}

Schloss, C. ^{[19
]}

de Bono, J. S. ^{[20
]}

机构：

[1] Univ Washington, Med Oncol, Seattle, WA 98195 USA

[2] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[3] Inst Paoli Calmettes, Med Oncol, Paris, France

[4] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[5] Studienpraxis Urol, Urol, Nuertingen, Germany

[6] Ctr Eugene Marquis, Med Oncol, Rennes, France

[7] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[8] Hop Europeen Georges Pompidou, Med Oncol, Paris, France

[9] Gustave Roussy Canc Campus, Med Oncol, Villejuif, France

[10] Paris Sud Univ, Villejuif, France

[11] Saarland Univ Hosp, Urol, Homburg, Germany

[12] Urol Canc Ctr, GU Res Network, Med Oncol, Omaha, NE USA

[13] Vall dHebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain

[14] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Paracelsus Med Univ, Urol, Nurnberg, Germany

[16] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[17] Macquarie Univ Hosp, Sydney, NSW, Australia

[18] Univ Wollongong, Med Oncol, Wollongong, NSW, Australia

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Royal Marsden NHS Fdn Trust, Med Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

612P

引用

页码：S652 / S653

页数：2

共 50 条

[31] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
De Bono, Johann S.
Goh, Jeffrey C. H.
Ojamaa, Kristiina
Rodriguez, Jose Maria Piulats
Drake, Charles G.
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, William R.
Fong, Peter C. C.
Piulats, Josep M.
Appleman, Leonard Joseph
Conter, Henry Jacob
Feyerabend, Susan
Shore, Neal D.
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
De Bono, Johann S.
Kam, Audrey E.
Emmenegger, Urban
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[33] Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Goh, J. C. H.
Piulats, J. M.
Gross-Goupil, M.
Vaishampayan, U. N.
de Wit, R.
Alanko, T. V.
Fukasawa, S.
Tabata, K.
Feyerabend, S.
Berger, R.
Wu, H.
Kim, J.
Schloss, C.
de Bono, J. S.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1331 - S1332
[34] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Petrylak, Daniel P.
Ratta, Raffaele
Matsubara, Nobuaki
Korbenfeld, Ernesto Pablo
Gafanov, Rustem
Mourey, Loic
Fer, Tilman Todenho Spacing Diaeresis
Gurney, Howard
Kramer, Gero
Bergman, Andre M.
Zalewski, Pawel
De Santis, Maria
Armstrong, Andrew J.
Gerritsen, Winald R.
Pachynski, Russell Kent
Saretsky, Todd L.
Ghate, Sameer R.
Li, Xin Tong
Schloss, Charles
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[35] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
Barroso-Sousa, Romualdo
da Fonseca, Leonardo Gomes
Souza, Karla Teixeira
Ribeiro Chaves, Ana Carolina
Kann, Ariel Galapo
de Castro, Gilberto, Jr.
Dzik, Carlos
MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 6
[36] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
Romualdo Barroso-Sousa
Leonardo Gomes da Fonseca
Karla Teixeira Souza
Ana Carolina Ribeiro Chaves
Ariel Galapo Kann
Gilberto de Castro
Carlos Dzik
Medical Oncology, 2015, 32
[37] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Fong, Peter C. C.
Todenhofer, Tilman
Laguerre, Brigitte
Arranz, Jose A.
Oudard, Stephane
Massard, Christophe
Heinzelbecker, Julia
Nordquist, Luke T.
Carles, Joan
Kolinsky, Michael P.
Augustin, Marinela
Gurney, Howard
Tafreshi, Ali
Li, Xin Tong
Qiu, Ping
Poehlein, Christian H.
Schloss, Charles
de Bono, Johann S.
EUROPEAN UROLOGY, 2023, 83 (01) : 15 - 26
[38] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
Yu, Evan Y.
Joshua, Anthony M.
Shore, Neal D.
Kramer, Gero
Hu, Haixia
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
[39] KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC).
Stein, Mark N.
Fong, Lawrence
Tutrone, Ronald F.
Mega, Anthony E.
Lobo, Maurice
Hong, Quan
Haas, Naomi B.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, D. P.
Li, B.
Schloss, C.
Fizazi, K.
ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351

← 1 2 3 4 5 →